YOLFTbeta
Onward Medical N.V.

Onward Medical N.V.

ONWD · BR · Healthcare / Biotechnology

1.70EUR-0.02 (-1.28%)

Price History

Full chart

Market Stats

Previous Close1.72
Open1.71
Day Range1.66 – 1.72
52-Week Range1.86 – 4.79
Volume223.81K
Market Cap131.41M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.85
Dividend Yield0.00%
Beta0.71
50-Day Avg2.49
200-Day Avg2.93

About

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. David L. Marver
  • Employees137
  • HeadquartersSchimmelt 2, Eindhoven, Netherlands, NL-5611, Belgium
  • Websitehttps://www.onwd.com

Leadership

  • Mr. David L. MarverCEO & Executive Director · b. 1968
  • Dr. Gregoire Courtine Ph.D.Co-Founder & Senior Advisor · b. 1975
  • Mr. Ali KiboroChief Financial Officer · b. 1976
  • Mr. Robert W. OdellVice President of Operations · b. 1960
  • Mr. Lorenzo FantiVice President of Legal
  • Mr. Sebastien CrosVice President of Communications
  • Mr. Alexandre CasteauHead of Strategy & Corporate Development
  • Ms. Julie CromDirector of People & Culture
  • Mr. Sean SciaraChief Commercial Officer
  • Ms. Shari O'QuinnChief Clinical, Regulatory & Quality Officer

Financials

Income Statement

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue474.00K554.00K580.00K1.22M2.08M532.00K77.00K3.78M
Growth (%)-+16.88%+4.69%+110.17%+70.30%-74.37%-85.53%+4809.09%
Cost of Revenue1.04M838.00K2.31M4.05M14.69M15.35M920.00K1.04M
Gross Profit-1.04M-838.00K-1.73M-2.83M-12.61M-14.82M-843.00K2.74M
Gross Margin-219.62%-151.26%-298.10%-231.99%-607.47%-2785.34%-1094.81%72.51%
Operating Expense7.36M9.93M11.55M23.21M16.32M20.64M35.68M43.66M
Operating Income-8.40M-10.77M-13.28M-26.04M-28.93M-35.46M-36.52M-40.92M
Operating Margin-1773.21%-1944.40%-2290.17%-2135.77%-1393.40%-6665.98%-47433.77%-1082.43%
EBITDA-8.17M-10.54M-13.06M-25.82M-28.19M-34.74M-32.87M-37.81M
EBITDA Margin-1723.84%-1903.25%-2252.41%-2118.29%-1357.76%-6529.51%-42685.71%-1000.34%
Net Income-9.91M-13.48M-20.01M-34.31M-32.77M-36.18M-35.73M-41.79M
Net Income Margin-2091.14%-2433.75%-3450.69%-2814.93%-1578.61%-6800.94%-46396.10%-1105.48%
R&D4.72M5.36M5.82M7.93M13.14M13.84M12.44M12.32M
R&D as % of Total Revenue996.20%966.79%1003.97%650.70%632.85%2601.69%16158.44%325.87%
Interest Expense1.49M2.67M4.48M5.66M1.51M1.39M2.00M2.22M
Interest Expense % of Total Revenue313.71%482.13%772.93%464.40%72.98%261.84%2596.10%58.62%

Balance Sheet

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.18M9.56M23.34M14.19M104.80M76.59M43.63M77.77M84.55M
Total Liabilities12.07M19.83M38.27M46.28M22.11M23.96M25.70M29.71M29.24M
Total Equity-3.89M-10.27M-14.92M-32.09M82.68M52.63M17.93M48.05M55.32M
Cash7.27M8.66M15.13M6.38M89.44M41.76M29.77M60.04M68.11M
Total Debt10.66M17.56M33.80M42.02M13.66M14.38M16.87M16.12M13.66M
Net Debt3.39M8.90M18.67M35.63M-75.78M-27.38M-12.89M-43.92M-54.45M

Cash Flow

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.16M-9.85M-12.90M-19.87M-26.68M-32.27M-31.76M-39.07M
Investing Cash Flow-103.00K-99.00K-173.00K-2.32M-20.42M19.58M-150.00K-432.00K
Financing Cash Flow8.65M16.40M4.37M105.36M-557.00K813.00K62.56M47.35M
Capital Expenditure103.00K124.00K173.00K2.32M417.00K422.00K150.00K432.00K
Free Cash Flow-7.26M-9.97M-13.07M-22.20M-27.10M-32.69M-31.91M-39.50M
FCF to OCF101.44%101.26%101.34%111.69%101.56%101.31%100.47%101.11%

Earnings

Report DateOct 13, 2021Apr 24, 2022Aug 28, 2022Mar 27, 2023Apr 1, 2025Sep 2, 2025Nov 24, 2025Apr 29, 2026Sep 9, 2026Mar 30, 2027
EPS Estimate0.000.000.000.000.00-0.000.00--
EPS Actual-0.30-2.27-0.53-0.56-0.32-0.470.000.00--
Surprise----------
TimingPre-marketPre-marketPre-marketAfter-hours-After-hours--After-hoursAfter-hours

Key Statistics & Ratios

Market Cap131.41M
Enterprise Value84.90M
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.61
Price / Book2.12
EPS-0.85
Book Value1.04
Revenue (TTM)8.42M
Gross Profit (TTM)6.35M
EBITDA-43.46M
Profit Margin0.00%
Operating Margin-556.66%
Return on Equity-90.85%
Return on Assets-35.30%
Shares Outstanding69.53M
Shares Float54.66M
Beta0.71
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%